Wildiers, Hans

Vascular Endothelial Growth Factor and Angiogenesis

Hoeben, A., Landuyt, B., Highley, M. S., Wildiers, H., Van Oosterom, A. T., & De Bruijn, E. A. (2004) · Pharmacological Reviews

Angiogenesis and VEGF in CancerLymphatic System and Diseases

Cited by 1,824

A single-cell map of intratumoral changes during anti-PD1 treatment of patients with breast cancer

Bassez, A., Vos, H., Van Dyck, L., Floris, G., Arijs, I., Desmedt, C., Boeckx, B., Vanden Bempt, M., Nevelsteen, I., Lambein, K., et al. (2021) · Nature Medicine

Cancer Immunotherapy and BiomarkersBreast Cancer Treatment Studies

Cited by 867

Screening tools for multidimensional health problems warranting a geriatric assessment in older cancer patients: an update on SIOG recommendations

Decoster, L., Van Puyvelde, K., Mohile, S., Wedding, U., Basso, U., Colloca, G., Rostoft, S., Overcash, J., Wildiers, H., Steer, C., et al. (2015) · Annals of Oncology

Frailty in Older AdultsNutrition and Health in Aging

Cited by 794

Associations of breast cancer risk factors with tumor subtypes: A pooled analysis from the breast cancer association consortium studies

Yang, X. R., Chang-Claude, J., Goode, E. L., Couch, F. J., Nevanlinna, H., Milne, R. L., Gaudet, M., Schmidt, M. K., Broeks, A., Cox, A., et al. (2011) · JNCI: Journal of the National Cancer Institute

Cancer Risks and FactorsBreast Cancer Treatment Studies

Cited by 691

Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial

Saura, C., Oliveira, M., Feng, Y.-H., Dai, M.-S., Chen, S.-W., Hurvitz, S. A., Kim, S.-B., Moy, B., Delaloge, S., Gradishar, W., et al. (2020) · Journal of Clinical Oncology

HER2/EGFR in Cancer ResearchLung Cancer Treatments and Mutations

Cited by 604

Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170

EMBRACE, Dunning, A. M., Collaborators, G. S., HEBON, kConFab Investigators, Michailidou, K., Kuchenbaecker, K. B., Thompson, D., French, J. D., Beesley, J., et al. (2016) · Nature Genetics

Genetic Associations and EpidemiologyEstrogen and related hormone effects

Cited by 161

Adapting care for older cancer patients during the COVID-19 pandemic: Recommendations from the International Society of Geriatric Oncology (SIOG) COVID-19 Working Group

Battisti, N. M. L., Mislang, A. R., Cooper, L., O'Donovan, A., Audisio, R. A., Cheung, K.-L., Sarrió, R. G., Stauder, R., Soto-Perez-de-Celis, E., Jaklitsch, M., et al. (2020) · Journal of Geriatric Oncology

COVID-19 and healthcare impactsFrailty in Older Adults

Cited by 79

How to Implement a Geriatric Assessment in Your Clinical Practice

Sattar, S., Alibhai, S. M. H., Wildiers, H., & Puts, M. T. E. (2014) · The Oncologist

Frailty in Older AdultsNutrition and Health in Aging

Cited by 75

Body mass index and breast cancer survival: a Mendelian randomization analysis

Guo, Q., Burgess, S., Turman, C., Bolla, M. K., Wang, Q., Lush, M., Abraham, J., Aittomäki, K., Andrulis, I. L., Apicella, C., et al. (2017) · International Journal of Epidemiology

Cancer Risks and FactorsGenetic Associations and Epidemiology

Cited by 64

Artificial intelligence electrocardiogram as a novel screening tool to detect a newly abnormal left ventricular ejection fraction after anthracycline-based cancer therapy

Jacobs, J. E. J., Greason, G., Mangold, K. E., Wildiers, H., Willems, R., Janssens, S., Noseworthy, P., Lopez-Jimenez, F., Voigt, J.-U., Friedman, P., et al. (2024) · European Journal of Preventive Cardiology

Chemotherapy-induced cardiotoxicity and mitigationECG Monitoring and Analysis

Cited by 49

Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer

Diéras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J.-P., Puhalla, S. L., Bondarenko, I., Campone, M., Jakobsen, E. H., et al. (2019) · Annals of Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 32

Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1 / 2 mutations and hormone receptor status from the phase-3 BROCADE3 trial

Ayoub, J.-P., Wildiers, H., Friedlander, M., Arun, B. K., Han, H. S., Puhalla, S., Shparyk, Y., Jakobsen, E. H., Wu, M., Bach, B. A., et al. (2021) · Therapeutic Advances in Medical Oncology

PARP inhibition in cancer therapyBRCA gene mutations in cancer

Cited by 17